Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis
A live, multi-source view of Olema Pharmaceuticals, Inc. (OLMA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Sector: Healthcare · Industry: Biotechnology · United States · 150 employees · olema.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Olema Pharmaceuticals, Inc. (OLMA) had a market capitalization of $940.6M (forward -4.0) and a beta of 1.99; the shares traded in a 52-week range of $6.65 – $36.26 (41.8% over the year).
- Market cap
- $940.6M
- Enterprise value
- $483.2M
- Forward P/E
- -4.0
- Price / book
- 2.18
- EPS (trailing)
- $-2.13
- EPS (forward)
- $-2.69
- Payout ratio
- 0.0%
- 52-week range
- $6.65 – $36.26
- 52-week change
- 41.8%
- Beta
- 1.99
- Average volume
- 1.3M
- Shares outstanding
- 87.5M
- Short % of float
- 21.95%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Olema Pharmaceuticals, Inc. (OLMA) last closed at $10.69 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price -0.1% versus its 20-day average, 20-day versus 50-day average spread -5.5%, MACD histogram 0.03.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 77/100.
Next scheduled company event: in 59 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of OLMA; corporate insiders filed 0 buys and 2 sells (1 filer, latest disclosure 2026-07-27). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Cyrus Harmon (0B/2S). Who is trading what
RapidTradeView pick record
OLMA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Olema Pharmaceuticals, Inc. (OLMA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell OLMA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.